Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

The mechanisms of action of PPARs

Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659

The PPARs: From Orphan Receptors to Drug Discovery

Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816

Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study

(2000) · Circulation · doi:10.1161/01.cir.102.1.21 · Cited by 1,273

Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay

Krey, G. D., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., & Wahli, W. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.0007 · Cited by 1,230

PPARs: therapeutic targets for metabolic disease

Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 716

An overview on biological mechanisms of PPARs

Kota, B. P., Huang, T. H.-W., & Roufogalis, B. D. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 681

Therapeutic roles of peroxisome proliferator-activated receptor agonists

Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646

PPARγ, the ultimate thrifty gene

Auwerx, J. (1999) · Diabetologia · doi:10.1007/s001250051268 · Cited by 612

Medical significance of peroxisome proliferator-activated receptors

Vamecq, J., & Latruffe, N. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10364-1 · Cited by 467

Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome

Tenenbaum, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1154 · Cited by 307

Differential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk

Uwaifo, G. I., & Ratner, R. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.006 · Cited by 43

Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

Teramoto, T., Shirai, K., Daida, H., & Yamada, N. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-29 · Cited by 41

Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease

Gilde, A. J., Fruchart, J., & Staels, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.097 · Cited by 42

Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies

Heald, M., & Cawthorne, M. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_2 · Cited by 41

Optimal Management of Combined Dyslipidemia: What Have We Behind Statins Monotherapy?

Tenenbaum, A., Fisman, E. Z., Motro, M., & Adler, Y. (2008) · Advances in cardiology · doi:10.1159/000115192 · Cited by 38

Amelioration of free fatty acid‐induced fatty liver by quercetin‐3‐O‐β‐D‐glucuronide through modulation of peroxisome proliferator‐activated receptor‐alpha/sterol regulatory element‐binding protein‐1c signaling

Wang, L. L., Zhang, Z. C., Hassan, W., Li, Y., Liu, J., & Shang, J. (2015) · Hepatology Research · doi:10.1111/hepr.12557 · Cited by 38

Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes

Tenenbaum, H., Behar, S., Boyko, V., Adler, Y., Fisman, E. Z., Tanné, D., Lapidot, M., Schwammenthal, E., Feinberg, M. S., Matas, Z., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.005 · Cited by 36

Mitochondrial Genetic Disorders: Cell Signaling and Pharmacological Therapies

Djouadi, F., & Bastin, J. (2019) · Cells · doi:10.3390/cells8040289 · Cited by 36

Selected Phyto and Marine Bioactive Compounds: Alternatives for the Treatment of Type 2 Diabetes

Reyes, B. A. S., Dufourt, E. C., Ross, J. A., Warner, M. J., Tanquilut, N., & Leung, A. B. (2017) · Studies in natural products chemistry · doi:10.1016/b978-0-444-64068-0.00004-8 · Cited by 39

NPY1R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression

Wittrisch, S., Klöting, N., Mörl, K., Chakaroun, R., Blüher, M., & Beck‐Sickinger, A. G. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.009 · Cited by 34

Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis

Bandyopadhyay, S. K., Samajdar, S. S., & Das, S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102174 · Cited by 35

The Biology of the Peroxisome Proliferator-activated Receptor System in the Female Reproductive Tract

Vélez, L. M., Abruzzese, G. A., & Motta, A. B. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319250010 · Cited by 34

Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract

Lian, J., Casari, I., & Falasca, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106025 · Cited by 37

Gemfibrozil, a Lipid-lowering Drug, Increases Myelin Genes in Human Oligodendrocytes via Peroxisome Proliferator-activated Receptor-β

Jana, M., Mondal, S., Gonzalez, F. J., & Pahan, K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.398552 · Cited by 34

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

Tenenbaum, A., & Fisman, E. Z. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-24 · Cited by 33

Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM)

Souto, S. B., Souto, E. B., Braga, D. C., & Medina, J. L. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1038-z · Cited by 36

Cardiovascular Disease and Modifiable Cardiometabolic Risk Factors

Cannon, C. P. (2008) · Clinical cornerstone · doi:10.1016/s1098-3597(09)62037-8 · Cited by 35

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate

Honda, A., Kamata, S., Akahane, M., Machida, Y., Uchii, K., Shiiyama, Y., Habu, Y., Miyawaki, S., Kaneko, C., Oyama, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094726 · Cited by 32

Development of Fibrates as Important Scaffolds in Medicinal Chemistry

Giampietro, L., Ammazzalorso, A., Amoroso, R., & Filippis, B. D. (2019) · ChemMedChem · doi:10.1002/cmdc.201900128 · Cited by 32

PPAR Agonists and Cardiovascular Disease in Diabetes

Calkin, A. C., & Thomas, M. C. (2008) · PPAR Research · doi:10.1155/2008/245410 · Cited by 30

Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate

Ru, S., Shen, C., Shafique, S., Mustapha, O., Hussain, T., Khan, I. U., Mehmood, Y., Anwer, K., Shahzad, Y., & Yousaf, A. M. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s235146 · Cited by 30

Direct antiatherosclerotic effects of PPAR agonists

Jandeleit-Dahm, K. A. M., Calkin, A. C., Tikellis, C., & Thomas, M. C. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32831f1b18 · Cited by 30

PCSK 9 in diabetic kidney disease

Elewa, U., Fernández‐Fernández, B., Mahíllo, I., Martín-Cleary, C., Sanz, A. B., Sánchez-Niño, M. D., & Ortíz, A. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12661 · Cited by 30

PPAR-γ signaling pathway in placental development and function: A potential therapeutic target in the treatment of gestational diseases

Giaginis, C., Spanopoulou, E., & Theocharis, S. E. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.8.1049 · Cited by 29

Peroxisome proliferator-activated receptor (PPAR) agonists as a potential therapy for inherited metabolic disorders

Seminotti, B., Grings, M., Glänzel, N. M., Vockley, J. E., & Leipnitz, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115433 · Cited by 27

PPAR‐alpha: therapeutic role in diabetes‐related cardiovascular disease

CHENG, A. Y. Y., & Leiter, L. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00747.x · Cited by 27

Treatment of metabolic syndrome with ankaflavin, a secondary metabolite isolated from the edible fungus Monascus spp.

Hsu, W.-H., & Pan, T. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5716-5 · Cited by 26

The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists

Matin, A., Doddareddy, M. R., Gavande, N. S., Nammi, S., Groundwater, P. W., Roubin, R. H., & Hibbs, D. E. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.040 · Cited by 26

Emerging drugs for non-alcoholic fatty liver disease

Federico, A., Niosi, M., Blanco, C. D. V., & Loguercio, C. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.1.145 · Cited by 25

Nuclear Receptors Database Including Negative Data (NR-DBIND): A Database Dedicated to Nuclear Receptors Binding Data Including Negative Data and Pharmacological Profile

Réau, M. F., Lagarde, N., Zagury, J., & Montès, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01105 · Cited by 25

Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility

Przybycień, P., Gąsior‐Perczak, D., & Placha, W. (2022) · Cells · doi:10.3390/cells11162569 · Cited by 26

Targeting Components of the Stress System as Potential Therapies for the Metabolic Syndrome

Yumuk, V. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1367.019 · Cited by 24

Role of PPAR-δ in the development of zymosan-induced multiple organ failure: an experiment mice study

Galuppo, M., Paola, R. D., Mazzon, E., Genovese, T., Crisafulli, C., Paterniti, I., Cuzzocrea, E., Bramanti, P., Kapoor, A., Thiemermann, C., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-12 · Cited by 24

Prediction of drug-induced mitochondrial dysfunction using succinate-cytochrome c reductase activity, QSAR and molecular docking

Rosell-Hidalgo, A., Moore, A. L., & Ghafourian, T. (2022) · Toxicology · doi:10.1016/j.tox.2022.153412 · Cited by 24

Drugs targeting peroxisome proliferator-activated receptors

Xie, Z., Xin, J., Huang, C.-J., & Liao, C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104318 · Cited by 25

Should We Use PPAR Agonists to Reduce Cardiovascular Risk?

Robinson, J. G. (2008) · PPAR Research · doi:10.1155/2008/891425 · Cited by 22

Update on the Prevention of Type 2 Diabetes

Karam, J. G., & McFarlane, S. I. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0163-x · Cited by 22

A novel plausible mechanism of NSAIDs-induced apoptosis in cancer cells: the implication of proline oxidase and peroxisome proliferator-activated receptor

Kazberuk, A., Zaręba, I., Palka, J. A., & Surażyński, A. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00140-z · Cited by 22

Role of selective peroxisome proliferator‐activated receptor modulators in managing cardiometabolic disease: tale of a roller‐coaster

Sahebkar, A., & Watts, G. F. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12277 · Cited by 21

Pleiotropic Effects of Glitazones: A Double Edge Sword?

Salomone, S. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00014 · Cited by 21

HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions

Ganjali, S., Momtazi‐Borojeni, A. A., Banach, M., Kovanen, P. T., Gotto, A. M., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.014 · Cited by 21

Hypertension in type 2 diabetes mellitus

Hayden, M. R., & Sowers, J. R. (2006) · Insulin · doi:10.1016/s1557-0843(06)80005-9 · Cited by 21

Macrophage fatty acid oxidation in atherosclerosis

Xiao, S., Qi, M., Zhou, Q., Gong, H.-Q., Wei, D., Wang, G., Feng, Q., Wang, Z., Liu, Z., Zhou, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116092 · Cited by 25

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

Tenenbaum, A., Boyko, V., Fisman, E. Z., Goldenberg, I., Adler, Y., Feinberg, M. S., Motro, M., Tanné, D., Shemesh, J., Schwammenthal, E., et al. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-18 · Cited by 20

Comparative Transcriptional Network Modeling of Three PPAR-α/γ Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes

Deehan, R., Maerz-Weiss, P., Catlett, N. L., Steiner, G., Wong, B., Wright, M., Blander, G., Elliston, K. O., Ladd, W., Bobadilla, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035012 · Cited by 20

Peroxisome proliferator-activated receptor β/δ agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice.

Paterniti, I., Mazzon, E., Riccardi, L., Galuppo, M., Impellizzeri, D., Esposito, E., Bramanti, P., Cappellani, A., & Cuzzocrea, S. (2012) · Surgery · doi:10.1016/j.surg.2012.02.004 · Cited by 20

Peroxisomal footprint in the pathogenesis of nonalcoholic steatohepatitis

Islam, S. M. T., Won, J., Khan, M., Chavin, K. D., & Singh, I. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.11.007 · Cited by 19

Preclinical Cancer Chemoprevention Studies Using Animal Model of Inflammation-Associated Colorectal Carcinogenesis

Tanaka, T. (2012) · Cancers · doi:10.3390/cancers4030673 · Cited by 18

Tesaglitazar, a Dual Peroxisome Proliferator- Activated Receptor Agonist (PPARα/γ), Improves Metabolic Abnormalities and Reduces Renal Injury in Obese Zucker Rats

Liao, J., Soltani, Z., Ebenezer, P. J., Isidro-Carrión, A. A., Zhang, R., Asghar, A., Aguilar, E. A., Francis, J., Hu, X. L., Ferder, L., et al. (2009) · Nephron Experimental Nephrology · doi:10.1159/000254567 · Cited by 17

Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications

Sookoian, S. C., & Pirola, C. J. (2007) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944707082702 · Cited by 16

Identification of dual PPARα/γ agonists and their effects on lipid metabolism

Gao, Q., Hanh, J., Váradi, L., Cairns, R. F., Sjöström, H., Liao, V. W. Y., Wood, P., Balaban, S., Ong, J. A., Lin, H.-Y. J., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.11.013 · Cited by 17

The Treatment of Dyslipidemia—What's Left in the Pipeline?

Rau, O., Zettl, H., Popescu, L. N., Steinhilber, D., & Schubert‐Zsilavecz, M. (2007) · ChemMedChem · doi:10.1002/cmdc.200700165 · Cited by 17

To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations

Sullivan, H.-J., Wang, X., Nogle, S., Liao, S., & Wu, C. F. (2020) · PPAR Research · doi:10.1155/2020/5314187 · Cited by 16

microRNA-27b regulates hepatic lipase enzyme LIPC and reduces triglyceride degradation during hepatitis C virus infection

Desrochers, G. F., Filip, R., Bastianelli, M., Stern, T., & Pezacki, J. P. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101983 · Cited by 16

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors

Zhang, L., Wang, S., Xu, W., Wang, R., & Wang, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048453 · Cited by 16

Disparate effects of 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid in vascular endothelial and smooth muscle cells and in cardiomyocytes

Sasson, S., & Eckel, J. (2006) · Archives of Physiology and Biochemistry · doi:10.1080/13813450600712035 · Cited by 16

Antifibrotic effects of bezafibrate and pioglitazone against thioacetamide-induced liver fibrosis in albino rats

Ibrahim, S. A., Mohamed, M. Z., El‐Tahawy, N. F. G., & Abdelrahman, A. M. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0159 · Cited by 15

Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol

Toth, P. P. (2007) · Current Atherosclerosis Reports · doi:10.1007/bf02693933 · Cited by 14

Peroxisome Proliferator-Activated Receptors as Molecular Targets in Relation to Obesity and Type 2 Diabetes

Šeda, O., & Šedová, L. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.6.587 · Cited by 15

Ipact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial.

Madrid-Miller, A., Moreno-Ruíz, L. A., Borrayo–Sánchez, G., Almeida‐Gutiérrez, E., Martínez-Gómez, D. F., & Aguilar, R. J. (2010) · PubMed · Cited by 14

Effect of structurally constrained oxime–ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists

Makadia, P., Shah, S. R., Pingali, H., Zaware, P., Patel, D., Pola, S., Thube, B. R., Priyadarshini, P., Suthar, D., Shah, M., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.023 · Cited by 14

Protective effects of the PPAR agonist bezafibrate against disruption of redox and energy homeostasis, neuronal death, astroglial reactivity, and neuroinflammation induced in vivo by D-2-hydroxyglutaric acid in rat brain

Ribeiro, R. T., Marcuzzo, M. B., Carvalho, A. V. S., Palavro, R., Castro, E. T., Pinheiro, C. V., Bobermin, L. D., Amaral, A. U., Leipnitz, G., Netto, C. A., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177186 · Cited by 13

Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: Effect of introduction of fluorine at the linker part

Kasuga, J.-I., Oyama, T., Hirakawa, Y., Makishima, M., Morikawa, K., Hashimoto, Y., & Miyachi, H. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.046 · Cited by 13

Peroxisome proliferator‐activated receptor α ligands and modulators from dietary compounds: T ypes, screening methods and functions

Yang, H., Xiao, L., & Wang, N. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12506 · Cited by 13

Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor α signaling

Zhao, Y., Okuyama, M., Hashimoto, H., Tagawa, Y., Jomori, T., & Yang, B. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.08.001 · Cited by 13

Peroxisome proliferator-activated receptor-γ ligands as bone turnover modulators

Giaginis, C., Tsantili‐Kakoulidou, A., & Theocharis, S. E. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.195 · Cited by 13

Prevention of type 2 diabetes: An update

Farag, A., Karam, J. G., Nicasio, J., & McFarlane, S. I. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0032-4 · Cited by 13

PPARs in Clinical Experimental Medicine after 35 Years of Worldwide Scientific Investigations and Medical Experiments

Skoczyńska, A., Ołdakowska, M., Dobosz, A., Adamiec, R., Gritskevich, S., Jonkisz, A., Lebioda, A., Adamiec-Mroczek, J., Małodobra-Mazur, M., & Dobosz, T. (2024) · Biomolecules · doi:10.3390/biom14070786 · Cited by 17

Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists

Gim, H. J., Li, H., Jeong, J. H., Lee, S. J., Sung, M., Song, M., Park, B., Oh, S. J., Ryu, J., & Jeon, R. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.046 · Cited by 12

Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE

Robinson, J. G. (2007) · Current Atherosclerosis Reports · doi:10.1007/bf02693930 · Cited by 12

Effects of PPARα on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?

Finck, B. N. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.2.161 · Cited by 12

Molecular dynamics in the supercooled liquid and glassy states of bezafibrate and binary mixture of fenofibrate

Afzal, A., Thayyil, M. S., Sivaramakrishnan, P. A., Urpayil, S., & Capaccioli, S. (2020) · Journal of Non-Crystalline Solids · doi:10.1016/j.jnoncrysol.2020.120407 · Cited by 11

ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis

Hove, J. L. K. V., Friederich, M. W., Hock, D. H., Stroud, D. A., Caruana, N. J., Christians, U., Schniedewind, B., Michel, C. R., Reisdorph, R. M., Gonzalez, E. D. J. L., et al. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101905 · Cited by 13

Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats

Khazaei, M., Salehi, E., & Rashidi, B. (2012) · International Journal of Peptides · doi:10.1155/2012/637212 · Cited by 11

PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery

Ortona, S., Barisione, C., Ferrari, P. F., Palombo, D., & Pratesi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133638 · Cited by 12

Ketogenic response to cotreatment with bezafibrate and medium chain triacylglycerols in healthy humans

Courchesne‐Loyer, A., St‐Pierre, V., Hennebelle, M., Castellano, C., Fortier, M., Tessier, D., & Cunnane, S. C. (2015) · Nutrition · doi:10.1016/j.nut.2015.05.015 · Cited by 10

Emerging Targets for the Treatment of Dyslipidemia

Tavridou, A., Ragia, G., & Manolopoulos, V. G. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794927757 · Cited by 10

Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice

Wang, Z.-J., Liu, Q., Li, P., Zou, C., & Shen, Z. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.10.042 · Cited by 10

Synthesis, biological evaluation and molecular modeling studies of the PPARβ/δ antagonist CC618

Kaupang, Å., Paulsen, S. M., Steindal, C. C., Ravna, A. W., Sylte, I., Halvorsen, T. G., Thoresen, G. H., & Hansen, T. V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.006 · Cited by 10

Bezafibrate improves mitochondrial function, blood-brain barrier integrity, and social deficits in models of 22q11.2 deletion syndrome

Crockett, A. M., Colόn, M. C. V., Kébir, H., Smith, F. M., Iascone, D. M., Ciesielski, B., Кошкин, С. А., Patterson, A. D., Rossano, A. J., Sehgal, A., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ads2116 · Cited by 11

Quantitative and Qualitative Analysis of CKD-501, Lobeglitazone, in Human Plasma and Urine Using LC–MS/MS and Its Application to a Pharmacokinetic Study

Kim, B., Shin, H.-S., Kim, J.-R., Lim, K.-S., Yoon, S. H., Yu, K., Shin, S., Jang, I., & Cho, J. (2012) · Chromatographia · doi:10.1007/s10337-012-2238-0 · Cited by 9

Bezafibrate Rescues Mitochondrial Encephalopathy in Mice via Induction of Daily Torpor and Hypometabolic State

Lyu, J.-W., Zhao, Y., Zhang, N., Xu, X., Zheng, R., Yu, W., Xin, W., Yan, C., & Ji, K. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01216-9 · Cited by 9

Red carpeting the newer antidiabetics.

Gude, D. (2012) · Europe PMC (PubMed Central) · doi:10.4103/0976-500x.95507 · Cited by 9

Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Durga, D. R., Mounika, N., Mudimala, P., & Adela, R. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01219-6 · Cited by 8

Antidiabetic effects of Eryngium billardieri hydrosol in the treatment of type 2 diabetic patients: A double-blind randomized clinical trial.

Chamgordani, Z. H., Mazaheri, M., Iraj, B., Baghshahi, H., & Sabouhi, F. (2023) · PubMed Central · doi:10.22038/ajp.2022.21175 · Cited by 8

Myocardial capillary density in normal and diabetic male rats: Effect of bezafibrate.

Khazaei, M., & Salehi, E. (2013) · Europe PMC (PubMed Central) · Cited by 8

Combination peroxisome proliferator‐activated receptor γ and α agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content

Balasubramanian, R., Gerrard, J., Man, C. D., Firbank, M., Lane, A. P., English, P. T., Cobelli, C., & Taylor, R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02906.x · Cited by 8

Bezafibrate induced increase in mitochondrial electron transport chain complex IV activity in human astrocytoma cells: Implications for mitochondrial cytopathies and neurodegenerative diseases

Ioannou, N., Hargreaves, I. P., Allen, G. F. G., Duberley, K. E. C., Land, J. M., & Heales, S. (2010) · BioFactors · doi:10.1002/biof.120 · Cited by 8

Poster Viewing Sessions PB01-B01 to PB03-V09

Badji, A., de la Colina, A. N., Sabra, D., Karakuzu, A., Bherer, L., Lamarre-Cliche, M., Stikov, N., Gauthier, C. J., Cohen‐Adad, J., & Girouard, H. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19851020 · Cited by 8

The Role Played by the Peroxisome Proliferator-Activated Receptor-β/δ (PPARβ/δ) Activator, GW501516, in Control of Fatty Acid Metabolism: A New Potential Therapeutic Target for Treating Metabolic Syndrome

Lee, J., & Chung, W. Y. (2011) · Endocrinology · doi:10.1210/en.2011-0211 · Cited by 6

Oral bezafibrate induces daily torpor and FGF21 in mice in a PPAR alpha dependent manner

Chu, L. P., & Swoap, S. J. (2011) · Journal of Thermal Biology · doi:10.1016/j.jtherbio.2011.11.011 · Cited by 6

Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer

Setayeshpour, Y., Chen, S., Dayanidhi, D. L., Lee, Y. W., Wu, S.-C., Aristizabal‐Henao, J. J., Wu, J., Lin, C., Setayeshpour, N., Federico, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72116-1 · Cited by 5

Capturing a Comprehensive Picture of Biological Events From Adverse Outcome Pathways in the Drug Exposome

Wu, Q., Bagdad, Y., Taboureau, O., & Audouze, K. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.763962 · Cited by 5

Dual PPRαϒ Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Menezes, A. D. S., Oliveira, V. M. R., Oliveira, I. C., de Sousa, A. M., Santana, A. J. P., Carvalho, D. P. C., Piai, R. F. P., Matos, F. H., de Paiva, A. M., & Reis, G. B. B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175674 · Cited by 4

Modulación del PPARα por agentes farmacológicos y naturales y sus implicaciones metabólicas

Panadero, M. I., González, M. D. C., Herrera, E., & Bocos, C. (2008) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(08)75789-9 · Cited by 4

Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?

Doggrell, S. A. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.9.1229 · Cited by 4

Primary Biliary Cholangitis

Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_3 · Cited by 3

The PPAR System in Diabetes

Ansquer, J.-C., & Foucher, C. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_19 · Cited by 3

Morbilidad y mortalidad en una serie de pacientes con neoplasias del peritoneo, tratados con citorreducción peritoneal más quimioterapia hipertérmica intraperitoneal en el Hospital Universitario de la Fundación Santa Fe de Bogotá (ONCOLGroup - estudio ATIA)

Arias-Amézquita, F., Otero, J. M., Londoño, E., Becerra, H., Carvajalino, S., Rodríguez, C. I., Granados, J., Quintero, P., Mora, M., Castro, C., et al. (2012) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2012.03.001 · Cited by 3

Effect of berberine on Cdk9 and cyclin T1 expressions in myocardium of diabetic rats

Jiyin, Z., Shiwen, Z., Jianlin, T., Xu, Y. X., & Ying, Y. (2008) · 中国人民解放军军医大学学报：英文版 · doi:10.1016/s1000-1948(08)60008-8 · Cited by 3

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 108

23 Role of Dual PPAR γ and α Agonists in Diabetes Mellitus—Have They Met a Road Block or They Are Dead?

Ganie, M. A., & Zargar, A. H. (2015)

Open Access Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators

Adeghate, E. A., Adem, A., Hasan, M. Y., Tekes, K., & Kalász, H. (2013)

Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators

Adeghate, E. A. (2011) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501105010093 · Cited by 58

Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies

Heald, M., & Cawthorne, M. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_2 · Cited by 41